CIANCETTA, Antonella
 Distribuzione geografica
Continente #
NA - Nord America 1.177
EU - Europa 277
AS - Asia 190
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
SA - Sud America 1
Totale 1.647
Nazione #
US - Stati Uniti d'America 1.175
IT - Italia 90
CN - Cina 75
TR - Turchia 52
SG - Singapore 49
PL - Polonia 38
UA - Ucraina 38
GB - Regno Unito 36
DE - Germania 28
SE - Svezia 21
FI - Finlandia 11
CZ - Repubblica Ceca 8
BE - Belgio 5
ID - Indonesia 5
HK - Hong Kong 4
CA - Canada 2
KR - Corea 2
RU - Federazione Russa 2
CL - Cile 1
EU - Europa 1
IR - Iran 1
NZ - Nuova Zelanda 1
TW - Taiwan 1
VN - Vietnam 1
Totale 1.647
Città #
Chandler 138
Fairfield 138
Ashburn 118
Ann Arbor 93
Houston 91
Woodbridge 85
Ferrara 54
Jacksonville 54
Wilmington 50
Seattle 49
Princeton 46
Cambridge 44
Warsaw 38
Singapore 28
Izmir 25
Shanghai 24
San Diego 18
Beijing 12
Washington 12
London 11
Nanjing 11
Boardman 9
Falls Church 9
Brno 8
Brussels 5
Changsha 5
Chicago 5
Jakarta 5
Milan 5
Redmond 5
Ferrara di Monte Baldo 4
Hong Kong 4
New York 4
Norwalk 4
Addison 3
Chiswick 3
Jiaxing 3
Jinan 3
Zhengzhou 3
Bremen 2
Hebei 2
Helsinki 2
Kilburn 2
Kunming 2
Nanchang 2
Novara 2
Tianjin 2
Yeongdeungpo-gu 2
Bologna 1
Brentford 1
Camerino 1
Changchun 1
Dearborn 1
Dong Ket 1
Dunedin 1
Forest City 1
Frankfurt am Main 1
Guangzhou 1
Hangzhou 1
Hounslow 1
Indiana 1
Islington 1
Kashan 1
Lanzhou 1
Mestre 1
Mountain View 1
Novokuznetsk 1
Padova 1
Palo del Colle 1
San Lazzaro di Savena 1
Saskatoon 1
Shenyang 1
Southfield 1
Southwark 1
Taipei 1
Tappahannock 1
Toronto 1
Venice 1
Wandsworth 1
Totale 1.275
Nome #
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 148
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 145
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation 121
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 121
null 118
The influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl moiety on the adenosine receptors affinity profile of pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c] pyrimidine derivatives 118
null 90
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 81
7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A(1) and A(2A) adenosine receptors. Molecular modeling and pharmacological studies 73
Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists 52
A 2a adenosine receptor: Structures, modeling, and medicinal chemistry 45
Bridging molecular docking to membrane molecular dynamics to investigate GPCR-ligand recognition: The human A2A adenosine receptor as a key study 32
Enhancing Ligand and Protein Sampling Using Sequential Monte Carlo 31
A3 adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states 29
Demystifying P2Y1 Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses 27
DockBench: An Integrated Informatic Platform Bridging the Gap between the Robust Validation of Docking Protocols and Virtual Screening Simulations 26
Deciphering the Complexity of Ligand-Protein Recognition Pathways Using Supervised Molecular Dynamics (SuMD) Simulations 24
A QM/MM study of the binding of RAPTA ligands to cathepsin B 24
Aquaporin inhibition by gold(III) compounds: New insights 23
Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer 22
Advances in Computational Techniques to Study GPCR-Ligand Recognition 22
Probe Confined Dynamic Mapping for G Protein-Coupled Receptor Allosteric Site Prediction 22
Activation of carboplatin by chloride ions: a theoretical investigation 21
Conjugates between minor groove binders and Zn(II)-tach complexes: Synthesis, characterization, and interaction with plasmid DNA 21
Design and in Vivo Characterization of A 1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series 21
Activation of Carboplatin by Carbonate 20
New Trends in Inspecting GPCR-ligand Recognition Process: the Contribution of the Molecular Modeling Section (MMS) at the University of Padova 17
“Exploring the Recognition Pathway at the Human A2A Adenosine Receptor of the Endogenous Agonist Adenosine using Supervised Molecular Dynamics Simulations” 17
Sensitivity of Binding Free Energy Calculations to Initial Protein Crystal Structure 16
Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT 16
Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study 16
Understanding allosteric interactions in G protein-coupled receptors using Supervised Molecular Dynamics: A prototype study analysing the human A3 adenosine receptor positive allosteric modulator LUF6000 16
“Bitopic Fluorescent Antagonists of the A2A Adenosine Receptor Based on Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine Functionalized Congeners” 15
Repurposing of a nucleoside scaffold from adenosine receptor agonists to opioid receptor antagonists 13
Pyrimidine nucleotides containing a (S)-methanocarba ring as P2Y6 receptor agonists 13
Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists 13
Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists 12
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-Triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists 12
Structure-Guided Modification of Heterocyclic Antagonists of the P2Y 14 Receptor 11
HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS 10
Structural probing and molecular modeling of the A3 adenosine receptor: A focus on agonist binding 9
South (S)- and north (N)-methanocarba-7-deazaadenosine analogues as inhibitors of human adenosine kinase 9
Synthesis and Spectroscopic Characterisation of a Heterodinuclear Iron(III)-Copper(II) Complex Based on an Asymmetric Dinucleating Ligand System 9
Perturbation of fluid dynamics properties of water molecules during G protein-coupled receptor-ligand recognition: the human A2A adenosine receptor as a key study 8
Targeting Aquaporin Function: Potent Inhibition of Aquaglyceroporin-3 by a Gold-Based Compound 8
Polypharmacology of conformationally locked methanocarba nucleosides 8
Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists 7
Influence of key amino acid mutation on the active site structure and on folding in acetyl-CoA synthase: A theoretical perspective 7
Implementing the “Best Template Searching” tool into Adenosiland platform 6
In silico 3D modeling of binding activities 4
Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: Meeting new challenges 3
Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design 3
Enhancing torsional sampling using fully adaptive simulated tempering 3
“Protein-ligand docking: virtual screening and applications to drug discovery” 2
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 1
Totale 1.761
Categoria #
all - tutte 16.256
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 592
Totale 16.848


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020216 31 8 7 36 14 27 20 19 19 17 9 9
2020/2021221 13 7 15 20 7 24 7 25 16 45 32 10
2021/2022366 2 16 6 100 16 5 18 61 20 7 13 102
2022/2023313 51 22 24 21 40 26 8 44 47 9 13 8
2023/2024271 16 25 27 12 28 48 14 24 7 4 4 62
2024/202514 14 0 0 0 0 0 0 0 0 0 0 0
Totale 1.761